Susan E. Barrowcliffe Net Worth

The estimated Net Worth of Susan E. Barrowcliffe is at least 1.4 百万$ dollars as of 19 November 2018. Susan Barrowcliffe owns over 40,000 units of Aimmune Therapeutics Inc stock worth over 1,402,250$ and over the last 9 years Susan sold AIMT stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Susan Barrowcliffe AIMT stock SEC Form 4 insiders trading

Susan has made over 9 trades of the Aimmune Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Susan exercised 40,000 units of AIMT stock worth 120,800$ on 19 November 2018.

The largest trade Susan's ever made was exercising 75,000 units of Aimmune Therapeutics Inc stock on 2 January 2018 worth over 226,500$. On average, Susan trades about 16,154 units every 57 days since 2016. As of 19 November 2018 Susan still owns at least 49,375 units of Aimmune Therapeutics Inc stock.

You can see the complete history of Susan Barrowcliffe stock trades at the bottom of the page.

What's Susan Barrowcliffe's mailing address?

Susan's mailing address filed with the SEC is 8000 Marina Blvd #200, Brisbane, CA 94005, USA.

Insiders trading at Aimmune Therapeutics Inc

Over the last 9 years, insiders at Aimmune Therapeutics Inc have traded over 19,285,948$ worth of Aimmune Therapeutics Inc stock and bought 61,698,079 units worth 2,225,231,200$ . The most active insiders traders include Des Produits Nestle S.A. So...、Patrick G Enright、Des Produits Nestle S.A.Nes.... On average, Aimmune Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of 21,038,606$. The most recent stock trade was executed by Des Produits Nestle S.A. So... on 13 October 2020, trading 54,117,287 units of AIMT stock currently worth 1,867,046,402$.

What does Aimmune Therapeutics Inc do?

Complete history of Susan Barrowcliffe stock trades at Aimmune Therapeutics Inc

Aimmune Therapeutics Inc executives and stock owners

Aimmune Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stacey Denenberg Seltzer,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Susan E. Barrowcliffe,
  General Manager, Europe
• Capital Partners Ii, Llc Ta...,
  
• Kathryn E Falberg,
  Director
• Daniel C Md Adelman,
  Chief Medical Officer
• Mary M. Rozenman,
  See Remarks
• Capital Management Ii, Llc ...,
  
• Capital Partners Ii, Llc Lo...,
  
• Gregory Behar,
  Director
• Douglas T. Sheehy,
  See Remarks
• Mark T Iwicki,
  Director
• Eric Bjerkholt,
  Chief Financial Officer
• Mark Mcdade,
  Director
• Warren L. De Souza,
  Chief Financial Officer
• Robert Myles Elfont,
  Chief Medical Officer
• Jayson Donald Alexander Dallas,
  President and CEO
• Health Science Us Holdings,...,
  
• Des Produits Nestle S.A.Nes...,
  
• Bakker Juliet Tammenoms,
  10% owner
• Stephen George Dilly,
  See Remarks
• Andrew Oxtoby,
  Chief Commercial Officer
• Capital Partners Ii, Llc Ta...,
  
• Patrick G Enright,
  Director
• Brett K Haumann,
  Director
• Des Produits Nestle S.A. So...,
  10% owner